Veraxa Biotech AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VRXA | HURA | CTMX | MGNX | PYXS | STRO | |
|---|---|---|---|---|---|---|
| Market cap | 161.20M | 121.08M | 527.32M | 236.96M | 240.11M | 220.20M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -3.1 | -5.1 | -2.5 | -1.8 | -2.1 |
| Price/book | -0.9 | 6.6 | 1.7 | 5.5 | 11.2 | -2.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −87.97% | −19.34% | −24.41% | +128.05% | −41.16% | +71.93% |
| Today | −9.52% | −3.06% | −5.84% | −0.53% | −0.99% | −6.94% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All VRXA news ›VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
Mr. Willener is an accomplished finance executive with more than three decades of international experience spanning investment banking, corporate finance, asset management and strategic leadership. Throughout his career, he has held senior…
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-... VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models…
Veraxa Biotech appoints Raju Willener as CFO
Veraxa Biotech (VRXA) announced the appointment of Raju Willener as CFO, effective immediately. Willener will report to Christoph Antz, CEO and ... Veraxa Biotech appoints Raju Willener as CFO Veraxa Biotech (VRXA) announced the…
Veraxa Biotech, Secarna announce initial results from AOC alliance
Veraxa Biotech (VRXA) and Secarna Pharmaceuticals announced initial results from their strategic research collaboration to develop next-generati... Veraxa Biotech, Secarna announce initial results from AOC alliance Veraxa Biotech (VRXA)…
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
ZURICH, SWITZERLAND, July 27, 2026 --VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the 'Company'), an emerging leader in designing novel cancer the... VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program…
VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on ... VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing VERAXA Biotech (NASDAQ: VRXA), a…
Leerink Partners Begins Coverage on Vera Therapeutics (NASDAQ:VERA)
Posted by Defense World Staff on Oct 12th, 2026 Leerink Partners began coverage on shares of Vera Therapeutics (NASDAQ:VERA – Get Free Report) in a research note issued to investors on Monday, Benzinga reports. The brokerage set a “market…
Nexentis Technologies Expands MitoCareX Bioinformatics Capabilities to Add Disease-Pathway Analysis to Drug-Discovery Platform
MitoCareX is expanding its bioinformatics expertise to enhance the analysis of disease biology in its drug-discovery platform. The goal is to incorporate disease-related insights early in the discovery process for better target evaluation…
Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis
On Oct 12, the day this news came out, the latest delayed price for NXTS is 4.84% below the previous close. Argus tracked a peak move of +10.5% during the session. Our momentum scanner has recorded 5 alerts for this stock so far that day.…
Virax Biolabs eliminates Nigel McCracken's COO role
Dr. Nigel McCracken is scheduled to leave employment on December 23, 2026, while remaining a director. Virax Biolabs Group Limited (VRAX) is restructuring senior management, eliminating the standalone Chief Operating Officer role and…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
markets.businessinsider.com6
-
seekingalpha.com2
-
stocktitan.net2
-
citybuzz.co1
-
defenseworld.net1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 17 articles, not a forecast.